News

Article

DuPont Adds New Alginate-Based Excipient to Pharma Portfolio

DuPont Nutrition & Health has added a new pharmaceutical excipient to the portfolio of ingredients for CPhI Worldwide 2014, in Paris this October.

DuPont Nutrition & Health has added a new pharmaceutical excipient to the portfolio of ingredients for CPhI Worldwide 2014, in Paris this October. The company will be exhibiting in hall 5, stand no. 5C89.

Alginate Pharma Grade is the first in a new series of alginate-based excipients developed to ensure the active ingredients in medicinal tablets reach their biological target intact and are released on time. DuPont’s pharma portfolio consists of excipients as well as actives. Production is based at the DuPont plant in Landerneau, France, where the French National Authority for Medicines and Health Products Safety has approved the dedicated production line.

“We have documented the Alginate Pharma Grade in a series of trials and expect to launch additional pharma-grade alginates for specific applications in the near future. Samples are available for functionality testing,” says Peter Janetzky, sales manager, Pharma & Industrials, DuPont Nutrition & Health, in a press statement.

Source: DuPont

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Related Videos
A global supply chain map, visualizing the complex network of transportation routes and distribution centers | Image Credit: © venusvi - stock.adobe.com
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Simona Guidi, Associate Director, ProPharma
Tore Bergsteiner
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More
Related Content